SimplePractice vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
All-in-one practice management platform for 185,000+ therapists, counselors, social workers, and wellness practitioners; Santa Monica-based;
About
SimplePractice is a Santa Monica-based practice management software company serving independent therapists, counselors, social workers, nutritionists, and other health and wellness practitioners. The platform provides scheduling, client intake forms, HIPAA-compliant telehealth video sessions, insurance billing, payment processing, progress notes, and client messaging in a unified system designed specifically for solo and small group private practices. SimplePractice handles the administrative burden of running a private practice — eligibility verification, superbills, ERA processing — enabling clinicians to spend more time with clients and less time on paperwork. The company serves over 185,000 practitioners across the United States and has become the dominant practice management platform in the mental health private practice segment. Founded in 2012, SimplePractice raised over $50M from investors including Susquehanna Growth Equity and has grown organically through referrals within the therapist community. It competes with TherapyNotes, TheraNest, and Therapy Brands in the mental health software market.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.